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A Double-blind Trial of Long-terrn Anticoagulant Treatrnent
after Myocardial Infarction
By
E. A. LoBLIcER, A. HoNsnN, F. Knoes, L. M. ven Dryr, N. FErrEs,
H. oe JoNcn AND H. C. Hnuren
After 1960 increasing opposition to long-
term anticoagulant treatment for coro-
nary thrombosis in our own as well as
in other countries (+,8, l+,16, 18, 26)
called for re-assessment of the value of
treatment, given for an unlimited period
to a steadily increasing number of pa-
tients controlled at our Thrombosis
Service. The value of a treatment given
for longer than one year had become
especially doubtful. Flence in 1963 we
decided to undertake a double-blind
clinical trial including all our patients
treated for longer than one year after
cardiac infarction. Fortunately the condi-
tion considered crucial for successful
anticoagulant treatment, i.e. effective
hypocoagulability, could be achi'eved
through the choice of a suitable drug
(7,I0,29) and particularly through the
facilities put at our disposal by the
Netherlands Thrombosis Service (20, 22,
23). This paper is the final report of the
trial.
Submitted for publication April 4, 1967.
Material and rnethods
In Jan. 196+, 417 patients treated with
coumarin drugs ,for more than one year
after a clinically and electrocardiographi-
cally proven cardiac infarction were being
cared for by the Thrombosis Service of
Leyden. Before grouping, 150 of these pa-
tients were excluded from the study for the
reasons indicated in table I.
No males younger than 45, or older than
75 years, and no females were included in
the study, the number of the latter being
too small to satisfy requirements for separate
statistical evaluation. Irnmobilized patients
were not admitted because vlhen not treated
with coumarin drugs these patients are known
to run a high risk of thromboembolic compli'
cations.
The remaining 267 patients, all of whom
had proven their willingness and suitability
for treatment during the year(s) before
admission to the study, were divided into
three age classes: 45-54, 55-64, and 65-
74 yean. The patients in each class were
subdivided into two chronological groups by
alternating allocation according to the date
of infarction, i,e. of admission to the
Thrombosis Service. The decision as to
5+9
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Tlrr,n I. Numbers ofpatients excluded from the trial, arranged according to reason for exclusion
Reason for exclusion Number of
Before
grouping
patients excluded
After grouping
Phenpro- Placebo
coumon
Total
Sex (women)
Age'< 45 years
) 75 years
On coumarin drug other than phenprocoumon
Hypertension (> 200 > 120)
Immobilization
Atrial fibrillation
Malignant tumour
Other medical reasons
Adequate supervision not feasible
Psychological reasons
Inappropriate inclusion
Death
Total
2
I
I
J
I
Tae1n II. Data concerning comparability of the two groups of patients treated with placebo and
phenprocoumon, respectively
Phenprocoumon Placebo
45-54 55-64 65-75 Total 45-54 55-64 65-75 Total
62
l 9
34
I
20
I
2
7
62
t 9
34
I
2
25
*
I
4
2
7
A
a
2
l
II
I
I
167t1150
Nurnber of patients 34
Mean age 50.5
Mean "pre-trial" anti-
coagulant period (mos) 35.4
Diabetes mellitus 2
Hypertension (> 180
> 100) 3
Re-infarction during "pre-
trial" anticoagulzint period I
Re-infafction as indica-
tion for long-term treatment 3
57
59.4
37.0
I
B
0
6
3 T
67.s
46.8
I
4
0
,
a
t2B 31 60
59.4 50.35 sg.4
39.4 39.2 39.3
4 0 1
31 122
69.1 59.6
4+.7 40.6
l 0  I
101 5
l 3
which group should tre treated with placebo
was made by lot for each class sepaxately.
As a result of this procedure, 134 patients
would have been treated with phenpro-
coumon and 133 withr placebo. Howeve{,'fe-
examination of the patients revealed four
inappropriate inclusions. (two with in-
sufficient evidence of cafdiac ihfarction,
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TeeI-n III. Comparability of the two groups of patients according tb length of the pre-trial anti-
coagulant treatment
Length of anticoagulant lreatment belore trial (mos)
t2- 24- 36- 48- 60- 72- 84- 96- 108-120
Phenprocoumon
Placebo
23  23
24  19
1 3  1 0
t 1  R
2 l l
3 -
39
36
I 6
1 B
and two females), two patiqnts suffering
frorn severe hypertension, and four cases of
atrial fibrillation. Two patients died, and five
patignts became bedridden between classi-
fication and the start of the trial, resulting
in a total of 17 drop-outs (columns 2 and 3
of table I).  Hence,250 patients f inal ly
entered the trial: 122 patients in the placebo
group and 128 patients in the phenpro-
coumon group. The period during which the
patients entered the trial lasted from the
end of March until the beginning of May
1964.
The criteria applied for comparability of
the two groups are indicated in tables II
and III. Table III, which gives the number
of patients in the two groups according to
the length of the pre-treatment period,
further illustrates the similarity of the two
groups.
At the start of the trial all patients were
told that they would be treated with a new
preparation, similar in its action to phen-
procoumon. The tablets, given us by F.
Hoffman-La Roche, Basel, rvere distributed
by the Thrombosis Service. The placebo
tablet consisted of saccharum lactis. The
phenprocoumon and placebo tablets were
identical in shape and colour. To prevent
mistakes, the letter M was not printed on
the placebo tablets. The therapeutic regimen
was the same in patients of both groups
except for the anticoagulant drug. Vitamin
Kr prophylaxis for tooth extraction was
given in all patients. Two of us (AH and
NF) were in charge of the dosage of phen-
procoumon and placebo. The dose of the
coumarin drug was prescribed on the basis
of the results of the coagulation test, the
dose of placebo according to that of phen-
procoumon in the preceeding year. As a
security-check a calendar with indication o'f
the daily dosage rvas mailed to the patients
after each coagulation test. The patients
were asked to cross out each dose of the
medicament as soon as it was taken. The
mean daily dose of phenprocoumon was
2.8 mg.
Attending physicians-general practitioners
and specialists-had given their full consent
to the trial. They were not informed about
the kind of treatment and they received,
irxtead of the result of the coagulation test,
a monthly reminder that the patient had
been checked for the long-term anticoagulant
treatment. In case of re-infarction, other kinds
of important cardiovascular deterioration,
appearance of dysbasia intermittens, cerebro-
vascular accident, or venous thrombosis and,
lastly, in case of bleeding, the atten'ding physi-
cian contacted one of us (EAL).The decision
as to the type of treatment was made before
the patient's status in the trial was known; if
the decision r'as "new indication for anti-
coagulant treatment", he was removed from
the trial.
The main criteria for determining the
value of the therapy were death-rate and
rate of re-infarction. The diagnosis re-
infarction based upon clinical, electro-
cardiographical and if available, biochemical
investigations, has been made by two dif-
ferent cardiologists (FK and LMvD). In
addition. the rate of other cardiovascular
complications was determined. Finally, 14
months after the beginning of the trial an
investigation ,intd complaints was made.
At the end of A,ug., 1965, the trial was
s
- 3 0
z
c 2 0
:
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THROMBOTEST ACTIVITY ( ' / . I
Fig. 1. Diagram of intensity and stability of
hypocoagulability as measured by means of
thrombotest activity. The values are grouped
in classes oI I Vo. Solid columns represent
values found in patients without contra-
indications. and hatched columns those found
in the patients with "relative" contra-indica-
tions (see text).
Tesr,n IV. Illustration of intensity and stability
of treatment: 696 thrombotest per-
centages (a representative sample
of the phenprocoumon group) were
classified as shown: 94.1 o/" of t}r.e
values lay below 15 o/", and 87.3 lo
between 5 o/o and 15 lo
Thrombotest, value-classes No of values
(%) (/class, o/o)
cases with no contra-indication we tried to
attain values of thrombotest within the range
ol 5 Vo-10 /6, whercas in cases with relative
contra-indications (almost 50% of the
patients displayed relative contraindications
such as age ) 65, hypertension, anamnestical
cerebrovascular accident, cured gastric or
duodenal ulcer) the corresponding range
was 7 Vo-13 %.
Fig. I and table IV demonstrate tlle
intensity of the coumarin effect as assessed
by thrombotest. For each of the 116 patients
still in the trial after one year of treatment,
six o,f the 12-18 thrombotest values obtained
during the fint 12 months of the trial (: a
total of 696 values) were collected by taking
the values of the first check of every 2-month
period. The logarithm of these values was
used for the calculation. The anti-log of the
mean of tlle six logarithmic values was
converted into /o TT and considered to be
representative of the level achieved in the
individual. In fig. 1 the individual average
values for these 116 patients are distributed
into classes oI | /6.
As fig. I shows, the 59 patients without
contra-indications were more intensively
treated than the 57 patients with relative
contra-indications. The overall mean throm-
botest activities were 7.5 /6 and 8.2 Vo,
respectively. The standard deviations of the
individual means were 1.25 % and 1.48 /6,
respectively, indicating that the stability of
hypocoagulability was somewhat better in
patients without contra-indications.
In addition, the variation o,f thrombotest
activity in individual patients was calculated
from the 116 x 6 valuesl the standard
deviation of the individual thrombotest
percentages was abort 2.9 /6.
Table IV, in which the 696 thrombotest
values are classified according to activity in
classes of 5 /e, illustrates the intensity and
stability of the treatment.
The thrombotest values of the eight
"sudden deaths", two re-infarctions, and two
irnportant cardiovascular deterioratiorx dur-
ing phenprocoumon treatment were analyzed
separately. They do not differ from those
found in the other patients either as to
< 5
f , - l  t ,
> 10-15
> 15-20
> 20-25
> 25-30.
> 3 0
6.8
68.2
l9 .  t
4.0
r .2
0.4
'0.3
finished. All patients were switched to
regular phenprocoumon therapy. Tablets
were no longer supplied gratuitously by the
Thrombosis Service; the patients had to
buy them on presiription.
The coagulation check consisted of
thrombotest performed on venous blood. In
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Tesle V. Classification of bleeding complica-
tions according to treatment, c.q.
severitv
Phenpro-
coumon
No change in dosage
Temporary lowering of
dosage
Administration of
vitamin K.
Blood transfusion
1 Two nacrohaematurias, one
bleeding.
'a Lethal intracerebral bleedins.
intdnsity or as to stability of the hypo-
coagulability.
The adequacy of the treatment was
further assessed by calculating the bleeding
frequency; tables V and VI show these
results.
Results
Immediately after the beginning of the
trial, a transitory increase of complaints
in patients of both groups was observed.
There was, however, no accumulation of
cardiovascular complications either in
the placebo or in the phenprocoumon
group during this period. The results of
the trial are summarized in table VII.
Details of the 16 "sudden" deaths, 14
re-infarctions, and 15 other cardio-
vascular complications, are given in
tables VIII, IX, and X.
Besides the patients ref€rred to in
tables IX and X, a-ll of whom were
switched from placebo back to phen-
procoumon, three other patients had to
be removed from the trial. two suffer-
Placebo
Cutaneous
Nasopharyngeal
Intestinal
Urogenital
Intracranial
Subconjunctival
5
7
I
2
I
I
subarachnoidal Touru VII. Summarv of the results
TeelB VI. Classification of bleeding complica-
tions according to localization
Localization Phenpro- Placebo
coumon
0
5
I
0
I
0
Phenpro- Placebo
coumon
1 l
r3
Number of patients
April 1964
Aug. 1965
Years of exposure to
risk
"Sudden" death
Re-infarction
Important cardiac
deterioration
Dysbasia intermittens
Cerebrovascular
accident
Venous thrombosis
Total cardiovascular
complications
Severe bleeding
complications
Number of drop-outs
r28
r12
l 6B
B
2
I
I
1 '
3 l
E
r22
B 1
138
B
Ll2
a
\2
,
J 5
3 l
'7
1 One death.
2 Sirbarachnoidal bleeding, with complete re-
covery.
3 Lethal intracerebral haemorrhage, already
tabulated under cerebrovascular accident.
ing from venous thrombosis while on
placebo and one displaying a sub-
arachnoidal bleeding during phen-
Procoumon therapy.
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Teer,e VIII. Data concerning patients who died "suddenly". The pre-treatment period is the
time of phenprocoumon treatment before the start of the trial
Pats Age Pre-treatment
period (mos)
Treatment
period (mos)
Cardiac symp-
toms before death
Phenprocoumon
HCGT
JGS
BG v. Ml
C v . R
wJ
HW
JJT
P J v . Z
Placebo
J  d . H
K R v . R
A v.d. V
JK
CSW
R v . D
J v . K
JZ
6 l
55
52
o+
55
6 l
J J
7 l
5 l
J I
56
7 '
57
62
52
1 5
29
79
50
R '
2 l
45
L Z
1 5
64
22
72
65
1 B
77
,
5
9
I
l l
1 2
l 6
l 6
25130
2
6
B
9
t 2
l 3
t 4
No
Yes
No
No
No
No
No
No
Yes
No
Yes
Yes
Yes
No
No
No
1 Diabetic.
Two patients, one treated with phen-
procoumon and the other with placebo,
who suffered a minor cerebrovascular ac-
cident that according to the consulting
neurologist was neither an indication
nor a contra-indication for anticoagulant
treatrnent, remained in the trial. The
same holds for a patient with signs of
retinal ischaemia while on phen.
procoumon.
The distribution of all cardiovascular
accidents (deaths, re-infarctions, and
other cardiovascular complications) over
observation time and age groups is
shown in fig, 2. Obviously, there is no
correlation between incidence and ob-
servation time in either the phen-
procoumon or the placebo patients. This
may be seen even more clearly from fig.
3, in which the incidence/observation
time corelation is depicted cumulative-
ly. On the other hand, there seems to be
a correlation between incidence and age:
durin$ the 16 1/2 months of observation,
18 /o of. the patients of the youngest
group displayed. a cardiovascular ac-
cident, whereas 15 /o of the middle-aged
and only 6 /o of. the elderly patients did
so. Statistiscally, this decline is signifi-
eant at a 5 /o level in the placebo group,
whereas no clear decline is to be seen in
the phenprocoumon group:
Of the 25 patients suffering from're-
infarction or some other cardiovascular
deterioration who were put back to
phenprocoumoir, two died from cardiac
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Teslr IX, Data for patients suffering from myocardial infarction
Age Pre-treatment
period (mos)
Treatment
period (mos)
Criteria
Clin. ECG SLDH
Phenprocouman
P d . K
N v . S
Placebo
HC
WV
WS'
J  d . w
ANM
GLJK \
PS3 
\
WMH
J  n . w
JZ
WH
N v . R
55
6 l
5B
60
59
64
49
5b;
L7
47
49
53
6 1
6 1
ztJ
T 4
66
70
63
3 l
N J
, ,
t 7
24
J I
45
52
28
4
r2
5/30
I
I
J
7
9
B .
1 0
r2
l 3
l 3
t 4 ,
+
+
+
+
-l-
+
+
+
+
+
+
+
+
+
t
-t- I
r Hypertension
2 Patient confined to home died on 7th day after infarction.
8 Diabetes.
- : SLDH not investigated.
insufficiency. None displayed another
cardiovascular accident during the
further observation period until the end
of the trial. On conventional statistical
treatment of the results in table VII, the
difference between the' 33 cardiovascular
accidents occurring in the placebo group
(the two venous thromboses were ex-
cluded) and the 12 accidents occurring
in the phenprocoumon group is signifi-
cant- at=a 0.1 /o level; for recurreRces
(12:2) and other cardiovascular com-
plications (13:-2) the differences are
significant at a 5 /o and 1" /o level, re-
spectively. Ilowever, with the statistical
approach applied by Bjerkelund'(2) the
differences both'for recurrences and for
other cardiovascular deteriorations are
significant at a | /o level (P recur-
rences < 0.005; P cardiovascular deterio-
rations <0.001). Bjerkelund's approach
takes into account the fact that the size
of the placebo group diminishes more
rapidly than that of the'phenprocoumon
group; the total time of treatment
(which can be defined as time of expo-
sure to risk) for the placebo and the
phenprocoumon groups amounted to 138
and 168 patient-years respectively.
Finalln in order to obtain more corn-
parable figures, the rate (%) 
"f 
the dif-
ferent types of accidents was calculated
by dividing the number of accidents by
the time of exposure to risk (in years),
the resulting value being multiplied by
100. Table XI gives the results.
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Tesr-n X. Data for patients suffering from other cardiovascular complications
PhenProcoumon
Cj v'd' Er
\ .  C B
Placebo
WMP
RW
Pats
JR' 59
cG 7r
P J v . H  6 2
W v . d K  6 l
CK 64
PZ 50
IAZ v.d. L 49
wK 54
FHTHJ s6
TJL 6+
W v . B  6 3
Progressive dysbasia
intermittens
Progressive angina
pectoris
Progressive angina
pectoris
Acute cardiac insuffi-
ciency
Prolonged attack of
angina Pectoris
Cerebrovascular accident
Cerebrovascular accident
Acute cardiac insufficiencY
Acute stenocardia
Progressive dYsbasia
intermittens
Progressive dysbasia
intermittens
Progressive dYsbasia
intermittens
Progressive angina
pectoris
Progressive angina
pectoris
Progressive dYsbasia
intermittens
56 24 l+
66  75  16
6 5 4 1 2
s + 7 9 3
Age Pre- Treat' Cardiovascular
treat- ment comPlications
ment Period
period (mos)
(mos)
Remarks
SympathectomY
Infarction not Proven
Confined to bed; dubious
ECG-changes
Admitted to hospital; du
ECG-changes; died 3 mon
after attack
Confined to bed; infarc
not proven
Lethal intracerebral hae
rhage
Complete recovery
Admitted to hospital; i
tion not Proven
Admitted to hospital; inf
tion not proven
Vascular prosthesis
SympathectomY
Confined to bed; checked
home for 4 weeks
Confined to bed; dubious
ECG-changes
SympathectomY
50
1 6
1 2
40
J O
69
69
22
22
5+
1B
J
J
B
B
B
B
B
l 0
I I
t 2
1 6
1 Diabetic.
2 Hypertension'
The death-rate, undoubtedly the main
criterion for the success of anticoagulant
treatment, was 4.8 % (81168 X 100) in
the phenprocoumon and 7.2 % (l0lI
X 100) in the Placebo grouP. If we
to the length of exposure to risk the
28
26
z \
22
20
t l r
oT
G
f - 1 8
c
o
C
t o
o
tr
A  l , r
c
o
8 1 2
L
o
.3 10
o
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t r i
I
a
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age (years)
re inrarct ion 
o! t?; lo l tn '
, , sudden"dea th  o  (e )  I
ltl'i,iii..o'.T"'' a (o) r
Fig. 2. Synopsis of cardiovascular accidents
related to time of treatment (ordinate) and
age (abscissa). After the end of the trial
(horizontal dotted line) complications oc-
curring in patients belonging to the former
placebo group are represented by punctuated
signs (* : same patient).
servation time of patients returned to
phenprocoumon (14 years for placebo
patients and two years for phen-
procoumon patients) the respective
OTHER CARDIOVASCULAR
DETERIORATION
observation time (monthsl
Fig. 3. Occurrence of cardiovascular complica-
tions related to observation time (cumulative
compilation). In the figure depicting cardio-
vascular death rate there are included, besides
the 16 sudden deaths, the two patients put
back on phenprocoumon shortly before their
death as well as the lethal cerebral hemorrhage
in a patient belonging to the placebo group.
figures become +.7 % (Bll70 x 100) and
7.2 % (l l l l52 X 100). There appears
to be no significant difference between
the death-rate in the two groups con-
sidered in either way. The re-infarction
rate, however, is distinctly higher in the
placebo group than in the phenpro-
coumon group (8.7 /o against 1.2 %),
the highest difference found in the
youngest age-group (15 % against0 /o).
A similar conclusion holds for the dif-
ference in incidence of other cardio-
vascular complications.
For the two younger age-groups taken
together, the rate of the sum of re-
infarctions and other cardiovascular
a l
I
I
i
I
l r  I
a i
I
I
I
I
I
I
I
I
I
t o i
a  ' t l
I
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Taslo XI. Incidence of cardiovascular accidents calculated for the total material and for t
three different age groups, classified according to type of accident. Incidence:
of accidents/yrs of exposure to risk, in o/o
45-54 55-64 65-75 A11
patients
Placebo
Years of exposure to risk
Mortality (%)
Recurrence (o/o)
Other cardiovascular complications ( o/o )
Phenprocoumon
Years of exposure to risk
Mortality (%)
Recurrence (o/o)
Other cardivascular complications ( o/o)
33.s
9
1 5 . 0
12.0
46.5
6 .5
0 .0
0.0
69
4 . 3
10 .1
10 .1
73
6.9
2.8
t . 4
35.5
5 .6
0 .0
5 .6
48.5
0 .0
0 .0
2 . 1
1 3 8
7.2
8 .7
9 .3
t68
+.8
t .2
r .2
TaelE XII. Number of cardiovascular complications classified according to length of pre-t
anticoagulant treatment
Length of anticoagulant treatment before trial (mos)
12-23 24-35 36-47 48-59 60-71 72-83 B4-120
Re-infarctions
Deaths
Other cardiovascular
complications
3  ( 1 )
7 (3) ( 1 )
( 1 )
( 1 )
( 1 )
J
2
i
a
I
.f
I
,  ( r \
L
4  ( 1 )
2  ( 1 )
Numbers within brackets refer to patients belonging to the phenprocoumon group.
Taeln XIII. Evaluation of complaints as expressed by patients without definite cardiovascul
complications, The feeling of improvement occurred significantly mqre of,ten
patients on phenprocournon than in patients on placebo (p<0.05)
Improved Unaltered Worse Total no
of pats
Phenprocoumon
Placebo
34.2 %
rs.3 %
s+.4 %
65.8 yo
rl.4 o/o
r4.5 %
1t4
76
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Tenr,n XIV. Ei'aluation of comp,laints as expressed by patients put back on phenprocoumon
Improved Deteriorated Un- Total
changed
Phenprocoumon
Re-infarctions
Other cardiovascular deterioration
Pla.cebo
Re-infarctions
Other cardiovascular deterioration
1
2
1
o
L
z
1 l
1 0
I
,
complications was slightly more than
nine times higher in patients on placebo
(24 %) than in those on phenprocoumon( 2 .6  %) .
Conspicuously enough, there is no cor-
relation between the occurrence of ac-
cidents and the length of the pre-treat-
ment period either for sudden deaths
and re-infarctions or for other cardio-
vascular deteriorations. This becomes
evident when the r,esults shown in tables
III and XII are tested together against
trend in a k X 2 contingency table with
approximation.
Between July 15 and Aug. 15,'1965,
190 of the 192 patients still included in
the study were asked, under blind con-
ditions, about theii complaints at the
end of the trial as compared to those
before its start, especially cardiac symp-
toms. Table XIII summarizes the results
of this interrogation. More of the pa-
tients tieated with phenprocoumon than
of those on placebo felt improved at the
end o{ the trial (significant at a 5 /o
level; 'test according to Yates and
Cochran). Of the 29 patients who rd-
turned from the placebo group to anti-
coagulants because of re-infarction and
other cardiovascular complications, 26
were still alive in Aug. 1965. Twenty-
Fig. 4. Tentative curve of correlation between
(re-)infarction rate and intensity of treat-
ment, constructgd upon data published or
furnished by authors of controlled clinical
trials.
five of them could be interrogated. Table
XIV shows the results: almost one-thircl
of the patients felt definite deterioration.
Only three felt improved.
The results of the interrogation rein-
force the evidence in favour of long-
term anticoagulant treatrnent, although
the patients' complaints are known to bc
the l'east objective criterion.
After discontinuance of the trial, al-
though the daily number of tablets to
be taken was not altered, the change in
posology caused in some patientl ir-
respective of the type of drug they had
bden treated withl a transient increase
of complaints siriiilar to those observed
immediately after the start of the trial.
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Patients who had been treated with
placebo were checked a fortnight aftet
the change of regimen. fn most of them
no important alteration in sensitivity to
phenprocoumon appeared to have taken
place. There were no important bleed-
ing complications. Interestingly enough,
however, as demonstrated in fig. 2, the
rate of cardior.ascular complications re-
mained unaltered for about three months
after discontinuance of the trial on Sept.
l: between Sept. and Dec. 1965, six ac-
cidents were obseryed in the former
placebo group as compared with only
two in the phenprocoumon group (as
indicated in fig. 2, the one of these two
who died from re-infarction had already
suffered re-infarction during the tiial).
Only in the course of the following seven
months of observation (until July 1966)
did the rate of complications decrease; it
then became similar for both groups. It
should be emphasized that, during this
second period of observation, no patient
had been lost from observation, that
there had been only one drop-out (due
to a gastric ulcer) and that no severe
bleeding complications were noted.
Discussion
The present study was undertaken in an
attempt to decide whether it is worth-
while to continue long-term anti-
coagulant treatment for more than
twelve months af.ter a myocardial in-
farction, a question raised by Bjerke-
lund at the Toronto meeting in 1961
(a). We were fully aware that only a
study satisfying the criteria of both a
doubl,e-blind clinical trial and an ade-
quate anticoagulant treatment could give
us the answer.
From the design of our trial, desc
under Material and methods. it can
seen that the conditi,ons of a dou
blind trial (1.3) are fulfilled: patien
were known to be suitable for oartici
tion in the trial; allocation into
procoumon and placebo groups w
made randomly; and the therapeu
regimen in both groups was the
except for the anticoagulant drug.
ever, as thele was selection, i.e. 'exclusi
of female patients, patients older than
and younger than 45 years, pati
suffering from hypertension, pati
physically unable to visit the labora
of the Thrombosis Servicg and pati
with atrial fibrillation, ,etc., this selec
could scarcely have biassed the st
of the two groups. Finally, the pati
can be considered representative
Leiden and its surroundings because
the local cardiologists and inte.
follow the same line of treatment
refer all their patients to the
Service for supervision of the an
coagulant treatment. With r.egard to
intensity and stability of the anti
lant action (table IV, fig. 1), the concl
sion seems warranted that most of t
patients had receiued adequate
ment. In cases without contra-i
tions our aim was a stable
labilitv with thrombotest values
5 /o and 10 Vo; as can be seen from fi
1, this was in the main achieved. f
patients with relative contra-indicati
coagulability was less uniformly
ed, as can be concluded from the la
standard deviation of the individ
means. But in this group, toq val
above 15 /o were exceptional.
Ijnder these conditions the res'u
:
[b.
;-
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obtained may indeed be regarded as
relevant to the discussion of long-term
treatment after myocardial infarction.
The difference in the rate of cardio-
vascular deaths-4.8 /o in the phen-
procoumon group as against 7.2 /o in
the placebo group-is not significant.
There is, however, a trend in favour of
anticoagulant treatment. This becomes
even more definite if this result is com-
bined with the rate of cardiova.scular
deaths observed in a parallel trial, per-
forrned under very similar conditions in
144 patients suffering from peripheral
sclerosis (17). In the latter study the
figures were 2.3 /o (two deaths) in the
phenprocoumon group against 9.5 %
(eight deaths) in the placebo group.
I{ere, too, no coruelation could be found
between occurrence of death and length
of the pre-treatment period. This sug-
gests that unlimited long-term anti-
coagulant treatment in patients suffering
from atherothrombosis prolongs life.
More obvious and undeniable is a re-
duction of morbidity. The difference be-
tween the two groups as to re-infarction
rate and rate of other cardiouascular
complications (important cardiac dete-
rioration, dysbasia intermittens, cerebro-
vascular accidents), if considered with
the statistical approach used by Bjerke-
lund (2), is highly significant. Phenpro-
coumon appears to provide a powerful
protection against such events, especially
in patients under 65 years of age (fig.2,
table XI). Moreover, the favourable
effect appears to be independent of the
duration of the anticoagulant treatment
( table xI I ) .
As far as we can judge from the litera-
ture, such {avourable results in patients
treated for more than twelve months
have seldom been obtained in the past.
This may be due to the exceptionally
high intensity and good stability of hypo-
coagulability achieved in our patients.
Although a similar quality of treatment
is known to be required for effective
prevention of the venous thrombo-
embolic diseases (32), its necessity is not
generally accepted for the prevention of
arterial thrombosis.
Neglect of the specific aim of anti-
coagulant treatment-therapeutically ef-
fective hypocoagulability-may in-
deed explain the lack of agreement
about whether patients with coronary
heart disease benefit from long-term
anticoagulant treatment. We therefore
attempted, for the 12 controlled clinical
trials thus far reported (1, 2, 5, B, ll,
12,  IB,  25,  27,30,  31,  34) ,  to  corre late
intensity of hypocoagulability with
therapeutic success as measured by re-
duction of the re-infarction rate ob-
served in coumarin-treated patients. The
results of the five studies suitable for
such an evaluat ion (1,2,5,  B,  31)  are
shown in fig. 4, in which the number of
(re-)infarctions occurring in patients
while on coumarin treatment is given as
percentage of the number found in the
control group. The interrsity of treat-
ment is'expressed as grand mean of per-
centage values for thrombotest activity.
In evaluating data concerning hypo-
coagulability, we took into account that
activities below 50 7o of. nor-rnal found
with the original P.P. method correspond
to approximately 513 of those found with
the original thrombotest (21, 33), the
difference being caused by preprothrom-
bin, a circulating anticoagulant appeab
- t ,
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ing in the circulation during coumarin
treatment ( 19) .
The only investigators who seem to
have reached an intensity of treatment
closely resembling ours, at least as far as
patients treated with phenprocoumon
are concerned (15), are Clausen et al.
(11). These authors achieved a con-
siderable reduction of the rate of recur-
rence in patients younger than 55 years
limited to the first year of treatment.
However, the importance of this result
is difficult to assess because irsufficient
data are given as to the comparability
of the coumarin and placebo grolrps. The
results, therefore, are excluded from
fig. 4.
The rather strong hypocoagulability
instituted by Borchgrwink (5) ir pu-
tients suffering from angina pectoris
receiving intensive treatment with phe-
nindione was accompanied by very
favourable clinical results. The mean
P.P. activity was 79 /o (: 1,1,.+ %
thrombotest activity); only about one-
fifth of the values ,exceeded 25 % P.P.
activity (: 15 /o thrombotest activity).
Entirely negative results were obtained
in patients treated during a supplemen-
tary period of observation when the
mean thrombotest value was 19 % (6).
Authors who have achieved moderate
intensity and stability of coumarin action
appear to have obtained partially
favourable results. Bjerkelund (2, 3, +)
concluded from his study that long-te1m
treatment with dicoumarol is primarily
indicated in the younger age-groups
(( 60 years old men), and that the ef-
fect achieved during the first 12 months
seems not to be lost after gradual cessa-
tion of therapy. In this first report Bjer-
kelund gives figures from wtrich a mean
P.P. activity of about 23 % (: I3.B /o
thrombotest activity) can be calculated
(2). Detailed figures indicate reasonable
stability of treatment.
Similar conclusions hold for the
British Medical Research Council
(B.M.R.C.) trial (27, 28) in which
phenindione had been the drug of
choice, although it is difficult to convert
prolongation. of prothrombin time into
percentage thrombotest; for acetone-
dried human brain thromboplastin,
which was used by the authors of the
B.M.R.C. trial, the prolongation sought,
2-2 Il2 times normal, probably cor-
responds to 5-12 /o thrombotest per-
bentage. IJnfortunately, exact figures
concerning intensity of treatment are not
given. There is, however, the interesting
finding of insufficient hypocoagulability
(prothrombin time ( 2 times normal)
both during the trial and before death in
about 50 /o of the patients who died of
re-infarction or other cardiovascular
cau$es, whereas in survivors this per-
centage was only one-third. The high
percentage of insufficient hlpocoagula-
bility demonstrates the rather low sta-
bility of treatment achieved in the British
trial.
An equally positive result was ob-
tained in the Veterans Administration
(V.A.) study (34): treated and un-
treated patients differed significantly
both in survival (0.05 > p ) 0.01) and
in re-admission for cardiac infarction
and congestive heart failure (p < 0.01).
Prothrombin activity in treated patients
seems to have been effectively reduced,
for with use of human brain thrombo-
plastin o-yer 80 /o of. the values were
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below 20 /o. This corresponds to a pro-
longation of the prothrombin time of
more than twice the normal (for human
brain thromboplastin, 20 /o prothtorn-
bin activity equals a thrombotest value
of  about  12 %).
Aspenstrtim and Korsan-Bengtsen ( 1)
conclude from their double-blind study
with dicoumarol and placebo that it is
'especially-poor-risk patients who benefit
frorn long-term prophylaxis. The intensity
of coumarin was comparable to that of
Bjerkelund, the mean P.P. value being
23 /a (personal cornmunication), which
corresponds to 13.8 /o thrornbotest.
A less intensive anticoagulant treat-
ment with phenindione, as applied by
Seaman et al. (31), did not produce
favourable results. These authors
achieved a mean P.P. activity of. 28 /o
(: 16.8 /o thrombotest activity), about
half of the values being higher than
25 % P.P. activity (: higher than
15 y'o thrombotest activity).
The completely negative result ob-
tained with dicouma,rol by Brown et al.
(8, 9) accompanied a grossly insufficient
anticoagulant ,effect; in a random sam-
ple, 67 /o of the thrombotest values
were found to lie between l0 y'a-30 /o
and even as much as 6 /o higher than
30 %.Moreover, the high incidence of
bleeding complications observed by these
authors suggests a low stability of hypo-
coagulability. The negative reports of
Lovell et al. (24, 25) and Conrad et al.
(12) are irrelevant to the present discus-
sion because the former give insufficient
and the latter no information at all con-
cerning intensity of treatment. Likewise
difficult to assess are the results reported
by Harvald et al. (18), because the
requirement of random allocation does
not seem to have been fulfilled (the
placebo group is much larger than the
phenprocoumon group) and no detailed
figures conoerning intensity or stability of
treatment are given.
Convincing confirmation of the cor-
rectness of our reasoning concerning the
correlation between intensity of anti-
coagulant treatment and the improve-
ment (fig. 4) has been found in the
report of a controlled clinical trial per-
formed by Rozenberg et al. (30). In this
trial, patients suffering from ischaemic
heart disease, in whom it was attempted
to maintain between 7 /o and 12 /o
thrombotest activity, did significantly
better than those within the L0 Va-20 7o
range.
A decision on whether intensity of
treatment is crucial calls for more trials
performed under the conditions of our
study. In our view, intensity and stability
of the coumarin action can be achieved
easily and safely, provided that a long-
acting coumarin preparation is used and
that the patients are carefully supervised.
An institution such as the organization o{
the Netherlands Thrombosis Service, in
which the members of the staff (physi-
cians and nurses) are fully responsible
for the coagulation check, and an ade-
quate dosage of the coumarin drug (20,
22,23) may be pre-requisites.
Surnrnary and conclusion
A double-blind clinical trial of long-term
anticoagulant therapy after myocardial
infarction was performed over 16 Il2
months at the Thrombosis Service of
L,eiden. Phenprocoumon and placebo
were the drugs of choice. Included in
"r
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the study were 250 male out-patients, complication. No blood transfusions
aged from +5 to .75, who had been were giveh and no lethal bleedings oc-
treated with phenprocoumon for at least curred (the patient who died of cer-ebral
12 months before the start of the trial. haemorrhage belonged to the placebo
The therapeutic regimen in both groups group).
was the same except for the anticoagu- A comparative study of our results
lant drug. and of those published earlier strongly
The incidence of cardiovascular suggests that the extent to which recur-
deaths in the phenprocoumon group was rent coronary thrombosis is prevented by
4.8 % as against 7.2 % in the placebo anticoagulant treatment depends prima-
group. This difference is not statistically rily on the intensity of hypocoagulability
significant. The number of re-infarctions achieved. Moderate hypocoagulability
and the number of other important (thrombotest values 12 %-25 /o) is of.
cardiovascular complications, however, limited or no value, whereas a suffi-
were both much lower in the phenpro- ciently intensive treatment (thrombotest
coumon group, the difference being sig- values of 5 /o-L2 /o) appears to im-
nificant at aI /o level. The two younger prove the prognosis of coronary heart
age-groups seem to have benefitted from disease for an unlimited period of time,
phenprocoumon treatment more than at least in ambulant male patients un-
the eldest group. The rate of occurrence der 65 years of age. The achievernent of
of complications was independent of the a sufficiently intensive and stable hypo-
length of pre-treatment with phenpro- coagulability may depend, however, on
coumon. tight supervision of the patients, such as
The favourable clinical results are is provided by the organization of the
based upon a high and stable intensity Netherlands Thrombosis Service, and on
of hypocoagulability. The mean throm- the use of phenprocoumon for its con-
botest activity was 7.5 % and 8.2 /o tn spicuously prolonged anticoagulant ef-
patients without and with relative fect.
contra-indications respectively, the
standard deviation of the individual References
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